United Health Products Q2 net loss narrows to $284,140; revenue flat with no revenue

• United Health Products posted a net loss of $284,140 for the quarter ended June 30, 2026, narrowing from $315,187 a year earlier.
• Operating loss improved to $166,850 from $268,356; revenue was flat with no revenue in both periods.
• Other expense widened to $117,290 from $46,831, on higher interest expense and a larger loss on derivative liabilities.
• FDA path remains in focus: NAMSA was selected July 6, 2026 to sponsor a planned IDE study for CelluSTAT as PMA work continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Health Products Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-005070), on August 14, 2026, and is solely responsible for the information contained therein.